Batoprotafib

Batoprotafib (TNO155) is a potent selective and orally active allosteric inhibitor of wild-type SHP2 (IC50=0.011 µM) . Batoprotafib has the potential for the study of RTK-dependent malignancies, especially advanced solid tumors[1].

Product Specifications

CAS Number

[1801765-04-7]

Product Name Alternative

TNO155

UNSPSC

12352005

Hazard Statement

H315, H319, H320

Target

Phosphatase; SHP2

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/batoprotafib.html

Purity

99.41

Solubility

DMSO : 66.67 mg/mL (ultrasonic)

Smiles

N[C@@H]1[C@H](C)OCC12CCN(C3=NC(N)=C(SC4=C(Cl)C(N)=NC=C4)N=C3)CC2

Molecular Formula

C18H24ClN7OS

Molecular Weight

421.95

Precautions

H315, H319, H320

References & Citations

[1]TNO155: SHP2 inhibitor|[2]Liu C, et al. Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling. Clin Cancer Res. 2021 Jan 1;27 (1) :342-354.|[3]Weiss A, et al. Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C. Cancer Discov. 2022 Jun 2;12 (6) :1500-1517.